
NeoGenomics (NEO) Stock Forecast & Price Target
NeoGenomics (NEO) Analyst Ratings
Bulls say
NeoGenomics is poised for long-term success with the recent coverage of its PanTracer LBx test by CMS' MolDX, anticipation of new revenue from the test in 2026, and its diverse revenue streams from clinical cancer testing, molecular and NGS testing, and clinical trials and research. However, challenges exist in the regulatory landscape and the integration of acquired businesses, and there are risks associated with government reimbursement and competitive factors. With strong financial performance in 1Q, the company plans to continue expanding its market share in areas such as liquid biopsy, minimal residual disease testing, and flow cytometry for heme malignancies.
Bears say
NeoGenomics is seeing positive growth in their oncology diagnostic testing and consultative services, but is facing challenges with below-average margins and potential competition from new proprietary technologies in the diagnostics industry. Their recent revenue growth target increase and plans to introduce new indications for MRD testing in the second half of 2026 may drive future multiple expansion, but concerns about profitability and competition could limit potential gains. The company's Q2 revenue guidance, with expected NGS growth and positive FCF in 2026, could offset lower margins and launch costs, but it remains to be seen if they can fully capitalize on their growth potential.
This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.
NeoGenomics (NEO) Analyst Forecast & Price Prediction
Start investing in NeoGenomics (NEO)
Order type
Buy in
Order amount
Est. shares
0 shares